Race Oncology Highlights Bisantrene at Healthcare Event

Race Oncology Ltd. (AU:RAC) has released an update.

Race Oncology Ltd will present at the E&P Small Caps Healthcare Conference, showcasing the progress of their lead drug, bisantrene (RC220), which has shown promise in cancer treatment with less cardiotoxicity. The presentation by Executive Chair Dr. Pete Smith will cover development updates and future clinical plans for bisantrene, a chemotherapeutic with a strong safety and efficacy profile. Race Oncology is actively seeking partnerships to expedite bisantrene’s availability to cancer patients globally.

For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.